A GLP1-RA and/or SGLT2 inhibitor with demonstrated evidence of benefit is recommended for individuals at high CV risk [44-48,51-57] [Grade A, Level 1A for dulaglutide, liraglutide, or subcutaneous semaglutide
Useful Links: Semaglutide (Ozempic, Wegovy) can cause nausea, vomiting, diarrhea, and constipationespecially early in treatment
However, in some cases, appetite suppression can be so strong that it leads to unintentional under-eating and associated health issues
If you experience any significant side effects or concerns, contact your healthcare provider for guidance
For meal planning guidance, the GLP-1 breakfast ideas article and protein shake recipes for GLP-1 users offer practical starting points